The global postpartum depression management market is poised to register a 3.8% CAGR, capturing a revenue share of USD 115.1 million in 2022, to reach USD 173.9 million by 2032.
In pregnancy and childbirth, there is an acute case of clinical depression that is called postpartum depression. It is a very common mood disorder examined specifically in pregnant mothers, though it affects both men and women.
As per a study published in a peer-reviewed journal, 1 out of 7 women who gave birth to a newborn suffered from postpartum depression. After three weeks of giving birth to a newborn, a mother starts feeling the effects of depression.
Postpartum depression management market growth is attributed to various factors that affect postpartum depression rates after pregnancy. These risk factors include hormonal and physical changes, a history of depression and stress, emotional imbalance, and bipolar disorder.
In pregnancy, mental disorders and mood swings are driving growth in the postpartum depression management market. Some of the major symptoms of postpartum depression among women include hopelessness, sadness, learning and memorizing, inability to focus, anxiety and exhaustion, loss of interest in self-care, and appetite problems.
| Report Attribute | Details |
|---|---|
| Postpartum Depression Management Market Value (2022) | USD 115.1 Million |
| Postpartum Depression Management Market Anticipated Forecast Value (2032) | USD 173.9 Million |
| Postpartum Depression Management Market Projected Growth Rate (2022 to 2032) | 3.8% |
To achieve better results, getting diagnosed by a doctor is crucial. Antidepressant prescriptions include Bupropion, Amitriptyline, Trimipramine, Fluoxetine, Paroxetine, Fluoxetine, Fluoxetine, Fluoxetine, Fluoxetine, and others. In contrast, counseling involves talk therapy with therapists or psychologists who provide management tips to help combat the conditions.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The growing demand for antidepressant drugs and talk therapies by expectant pregnant mothers is projecting the growth of the postpartum depression management market. Therefore, spending on postpartum depression management is increasing over time.
The postpartum depression management market is growing worldwide as women across the globe are lately experiencing postpartum depression as they find it difficult to cope with new responsibilities. The postpartum depression management market includes various home remedies that involve maintaining healthy lifestyle choices, avoiding isolation, to set realistic expectations.
Based on treatment type, anti-depressants are the most commonly used treatment methods over therapies as anti-depressants provide fast treatment and promising results in less time as compared with psychotherapies.
The anti-depressants treatment segment thus accounts for the largest revenue share in the postpartum depression management market. The segment is anticipated to follow the same trend in the postpartum depression management market over the next few years. As a result, women prefer it over psychotherapies to achieve faster results.
Some of the key factors driving the growth of the postpartum depression management market include the rise in risk factors associated with postpartum depression. These include the growing preference of women for the treatment of postpartum depression.
Women have become more aware of postpartum depression management and are more inclined to seek early treatment and therapies, which is further driving the global market for postpartum depression management.
It is expected that postpartum depression management market growth will be constrained by negligence and unacceptance of the condition, along with an inability to detect depression.
The demand for postpartum depression management has increased in the North American region. North America is anticipated to control a postpartum depression management market share of 37.5% in 2022.
In the last decade, North America has held the largest revenue share in the global postpartum depression management market on account of rising awareness among women regarding postpartum depression. It also enhanced decision-making by women with high educational attainment and easy availability of psychotherapy sessions with specialized doctors.
Europe's Postpartum Depression Management is predicted to experience significant growth and hold a market share of 29% in 2022. Mental health awareness is increasing among individuals and major companies are investing in countries in this region, which is driving revenues in the Europe postpartum depression market.
The market for postpartum depression in Europe is expected to be driven by an increasing number of initiatives to treat postpartum depression through telemedicine virtual support over calls and online counseling, as well as an increasing number of support groups and mental health communities for mothers.
Principal Consultant
The start-up ecosystem in the postpartum depression management market is clouded by several pharmaceutical companies, including Marinus Pharma and others, who are actively developing therapies to grow the postpartum depression management market share. In addition, they manufacture novel therapies to transform the treatment paradigm of the postpartum depression management market.
Sage Therapeutics and Marinus Pharmaceuticals are two major players developing therapies for postpartum depression (PPD). There will be a significant impact on the postpartum depression (PPD) market from the launch of new therapies such as SAGE-217 and Ganaxolone.
The postpartum depression management market is consolidated with a presence of a few strong players from around the globe. Some of the key players present in the global postpartum depression management market are Sage Therapeutics Inc., Cipla Limited, Sun Pharmaceutical Industries Ltd., Anikem Laboratories, Intas Pharmaceuticals Ltd., Mylan N.V., Sumika Fine Chemicals Co Ltd., and others.
emerging trends in the postpartum depression management market are brought about as a result of the major players' adoption of several growth strategies, including product launches, acquisitions, and collaborations.
Some of the recent developments in the Postpartum Depression Management market are as follows:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 3.8% from 2022 to 2032 |
| Base Year for Estimation | 2022 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment Type, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; The Asia Pacific excluding Japan; Japan; The Middle East and Africa |
| Key Countries Profiled | The USA, Canada, Brazil, Argentina, Germany, The UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, GCC Countries, South Africa |
| Key Companies Profiled | Sage Therapeutics Inc.; Cipla Limited; Sun Pharmaceutical Industries Ltd.; Anikem Laboratories; Intas Pharmaceuticals Ltd.; Mylan N.V.; Sumika Fine Chemicals Co Ltd. |
| Customization | Available Upon Request |
The postpartum depression management market is likely to account for USD 173.9 million by 2032.
North America is likely to hold a postpartum depression management market share of 37.5% in 2022.
The global postpartum depression management market is set to advance at a CAGR of 3.8% from 2022 to 2032.
The postpartum depression management market is projected to grow to USD 115.1 million in 2022.
1. Executive Summary | Postpartum Depression Management Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment 5.1. Anti-Depressant Drugs 5.2. New Anti-Depressant Drugs 5.3. SAGE-547 5.4. Bupropion 5.5. Escitalopram 5.6. Fluoxetine 5.7. Paroxetine 5.8. Sertraline 5.9. Old Anti-Depressant Drugs 5.10. Amitriptyline 5.11. Desipramine 5.12. Others 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 6.1. Hospital Pharmacies 6.2. Retail Pharmacies 6.3. Drug Stores 6.4. E-commerce 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. SAGE Therapeutics Inc. 15.2. Cipla Limited 15.3. Sun Pharmaceutical Industries Ltd. 15.4. Anikem Laboratories 15.5. Intas Pharmaceuticals Ltd. 15.6. Mylan N.V. 15.7. Sumika Fine Chemicals Co Ltd. 15.8. Aurobindo Pharma 15.9. Lupin 15.10. Accord Healthcare 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Postpartum Depression Management Market
